Innoviva Inc
$ 23.42
0.04%
24 Feb - close price
- Market Cap 1,659,873,000 USD
- Current Price $ 23.42
- High / Low $ 23.44 / 22.84
- Stock P/E 13.37
- Book Value 13.51
- EPS 1.66
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.15 %
- 52 Week High 24.01
- 52 Week Low 16.52
About
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Analyst Target Price
$36.40
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-02-29 | 2023-11-01 | 2023-08-02 | 2023-05-09 | 2023-02-28 |
| Reported EPS | 0.3846 | 0.77 | -0.7429 | 0.26 | 0.12 | -0.55 | 0.46 | 0.76 | 0.98 | 0.02 | 0.42 | -0.98 |
| Estimated EPS | 0.4 | 0.5 | 0.33 | 0.41 | 0.27 | 0.24 | 0.17 | 0.23 | 0.27 | 0.26 | 0.23 | 0.23 |
| Surprise | -0.0154 | 0.27 | -1.0729 | -0.15 | -0.15 | -0.79 | 0.29 | 0.53 | 0.71 | -0.24 | 0.19 | -1.21 |
| Surprise Percentage | -3.85% | 54% | -325.1212% | -36.5854% | -55.5556% | -329.1667% | 170.5882% | 230.4348% | 262.963% | -92.3077% | 82.6087% | -526.087% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.34 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None |
| Amount | $0.25 | $0.25 | $0.25 | $0.25 | $0.25 | $5.571428571 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INVA
2026-02-20 01:57:30
Innoviva, Inc. announced its management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 10:00 a.m. E.T. The conference will be held virtually, and a live webcast will be available on the Investor Relations section of the Company’s website. Innoviva is a diversified holding company with a royalties portfolio, a critical care and infectious disease platform (Innoviva Specialty Therapeutics), and strategic investments in healthcare assets.
2026-02-19 13:01:46
Innoviva, Inc. (NASDAQ: INVA) will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 10:00 a.m. E.T. The conference will be held virtually, and a live webcast will be available on the company's investor relations website, with an archived replay accessible afterward. Innoviva is a diversified holding company with a royalties portfolio, a critical care and infectious disease platform (Innoviva Specialty Therapeutics), and strategic healthcare investments.
2026-02-19 13:01:46
Innoviva, Inc. will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 10:00 a.m. E.T. The virtual event's webcast will be accessible through the Investor Relations section of the company's website. Innoviva is a diversified holding company with a royalties portfolio, the Innoviva Specialty Therapeutics platform, and healthcare investments, including respiratory assets with GSK and various infectious disease and critical care assets.
2026-02-17 14:28:14
BTIG initiated coverage on Innoviva Inc. (NASDAQ:INVA) with a Buy rating and a $35.00 price target, expecting the company to benefit from over $1.2 billion in royalty rights by 2030 for two COPD and asthma therapies. Innoviva is considered undervalued, holding more cash than debt, and has a strong financial position, with plans to redeploy capital into infectious disease therapies, strategic investments, and shareholder returns. The company's recent acquisition of an extended-release platform and potential accretive acquisitions, alongside expected net income growth, present significant upside potential for 2026.
2026-02-17 14:27:33
BTIG has initiated coverage of Innoviva (INVA) with a Buy recommendation, according to a Fintel report from February 17, 2026. Analysts project a 46.04% upside to an average one-year price target of $33.15/share. Fund sentiment indicates a slight decrease in the number of institutional owners, though the put/call ratio suggests a bullish outlook.
2026-02-17 11:58:27
BTIG has initiated coverage on Innoviva (INVA) with a 'Buy' rating and a price target of $35.00, according to analyst Julian Harrison. This new rating adds to the mixed sentiment for INVA, which has seen varying ratings and price targets from other firms like HC Wainwright & Co., Cantor Fitzgerald, Goldman Sachs, and Oppenheimer. Innoviva is a healthcare company with a portfolio of royalties and operating assets, and while analysts forecast an average upside of 43.17%, GuruFocus estimates a 13% downside based on its GF Value.
